Episurf Medical

• 72% growth in customer base and 43% growth in gross order intake
• 510(k) clearance received for Episealer® Patellofemoral System, and timetable communicated for 510(k) application for Episealer MTP-System
• Strengthening of commercial organization and preparation for US launch ongoing

"Today we are reporting on yet another quarter with clear steps in the right direction. The key metric of the number of surgeons using the Episealer grew by 72% in the quarter, and gross order intake was up by 43%. We clearly experienced positive developments in our commercial activities during the end of the year. Within product development, we concluded the year with a major milestone being achieved - namely, the 510(k)-clearance for the Episealer® Patellofemoral System. In 2023, it is important that we take the next steps as a company, broadening the user base globally, including the marketing of our first commercially available product in the US," says Pål Ryfors, CEO Episurf Medical.

Fourth quarter 2022 compared to 2021, Group

• Gross order intake amounted to SEK 2.2m (1.6)
• Order book amounted to SEK 2.0m (1.3)
• Group net sales amounted to SEK 1.8m (1.5)
• Loss for the period amounted to SEK -23.7m (-18.9)
• Earnings per share amounted to SEK -0.09 (-0.08)

Twelve months 2022 compared to 2021, Group

• Gross order intake amounted to SEK 7.1m (6.5)
• Group net sales amounted to SEK 6.6m (6.5)
• Loss for the period amounted to SEK -77.3m (-69.3)
• Earnings per share amounted to SEK -0.29 (-0.31)
   

Significant events during the fourth quarter

• Episurf Medical received FDA 510(k) clearance for Episealer® Patellofemoral System
• Episealer® Knee technology and clinical results were presented at scientific congresses in the US and Poland
• Episurf Medical presented commercial focus areas at the company's Capital Markets Day